Brand-name drug
Rasuvo price, strengths & recalls
Brand of methotrexate (generic)
Pharmacies pay $577.45 for 0.8 mL of Rasuvo 50 mg/mL, 0.2 mL auto-injector this week, and from $573.90 to $579.18 across its 7 priced strengths and forms. The generic, methotrexate, costs pharmacies from $3.50. It is in shortage (unavailable). It has 14 recalls on record, none ongoing. Its official label last changed on December 18, 2025.
UnavailableBrand- Fair cash price
- $674.57
- Strengths
- 7
- Makers
- 1
- Updated
- Nov 11
Rasuvo price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 50 mg/mL, 0.15 mL auto-injector Brand | $960.29 | $576.18 / 0.6 mL |
| 50 mg/mL, 0.2 mL auto-injector Brand | $721.81 | $577.45 / 0.8 mL |
| 50 mg/mL, 0.25 mL auto-injector Brand | $574.87 | $574.87 / 1 mL |
| 50 mg/mL, 0.3 mL auto-injector Brand | $480.36 | $576.43 / 1.2 mL |
| 50 mg/mL, 0.35 mL auto-injector Brand | $409.93 | $573.90 / 1.4 mL |
| 50 mg/mL, 0.4 mL auto-injector Brand | $361.99 | $579.18 / 1.6 mL |
| 50 mg/mL, 0.5 mL auto-injector Brand | $289.09 | $578.18 / 2 mL |
Rasuvo vs generic methotrexate
GenericMethotrexate pricesSupply status: shortages & recalls
Shortages
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) Multiple Dose Vial PREMIERProRx (NDC 61703-161-05)Next Delivery: July 2027; Estimated Recovery: September 2027; Shortage per Manufacturer: Manufacturing Delay
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)
- Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)
- Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)
- Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)Check wholesaler for inventory
- Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)Check wholesaler for inventory
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: Jan 2027
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)Estimated recovery: TBD
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)Estimated recovery: TBD
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 14 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Rasuvo
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use RASUVO® safely and effectively. See full prescribing information for RASUVO. RASUVO (methotrexate) injection, for subcutaneous use Initial U.S. Approval: 1953
WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY AND DEATH
Rasuvo should be used only by physicians whose knowledge and experience include the use of antimetabolite therapy. Because of the possibility of serious toxic reactions (which can be fatal), Rasuvo should be used only in patients with psoriasis or rheumatoid arthritis with severe, recalcitrant, disabling disease which is not adequately responsive to other forms of therapy. Deaths have been reported with the use of methotrexate in the treatment of malignancy, psoriasis, and rheumatoid arthritis. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities. Patients should be informed by their physician of the risks involved and be under a physician's care throughout therapy [see Warnings and Precautions (5.1)].
1.
Methotrexate can cause embryo-fetal toxicity, including fetal death. Use is contraindicated during pregnancy. Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females and males of reproductive potential to use effective contraception during and after treatment with Rasuvo [see Warnings and Precautions (5.2), Contraindications (4), and Use in Specific Populations (8.1, 8.3)].
2.
Methotrexate elimination is reduced in patients with impaired renal functions, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of Rasuvo administration [see Warnings and Precautions (5.6)].
3.
Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs) [see Warnings and Precautions (5.1) and Drug Interactions(7.1)].
4.
Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. Liver biopsy after sustained use often shows histologic changes, and fibrosis and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or abnormal liver function tests in the psoriasis population. For this reason, periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid arthritis population [see Warnings and Precautions (5.1)].
5.
Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. It is not always fully reversible and fatalities have been reported. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation [see Warnings and Precautions (5.1)].
6.
Diarrhea and ulcerative stomatitis require interruption of therapy: otherwise, hemorrhagic enteritis and death from intestinal perforation may occur [see Warnings and Precautions (5.1)].
7.
Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue Rasuvo first and, if the lymphoma does not regress, appropriate treatment should be instituted [see Warnings and Precautions (5.8)].
8.
Like other cytotoxic drugs, methotrexate may induce "tumor lysis syndrome" in patients with rapidly growing tumors [see Warnings and Precautions (5.9)].
9.
Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy [see Warnings and Precautions (5.1)].
10.
Potentially fatal opportunistic infections, especially Pneumocystis jiroveci pneumonia, may occur with methotrexate therapy [see Warnings and Precautions (5.1)].
11.
Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis [see Warnings and Precautions (5.10)].
WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO- FETAL TOXICITY AND DEATH
See full prescribing information for complete boxed warning.
Serious toxic reactions and death have been reported with the use of methotrexate. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities (5.1).
Methotrexate can cause embryo-fetal toxicity, including fetal death. Use is contraindicated during pregnancy (4). Advise females and males of reproductive potential to use effective contraception during and after treatment with methotrexate. (5.2, 8.1, 8.3).
Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs) (5.1).
Hepatotoxicity, fibrosis, and cirrhosis may occur after prolonged use (5.1).
Methotrexate may cause interstitial pneumonitis at any time during therapy and has been reported at low doses. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation (5.1).
Diarrhea, ulcerative stomatitis, hemorrhagic enteritis, and death from intestinal perforation may occur (5.1).
Severe, occasionally fatal, skin reactions have been reported (5.1).
Potentially fatal opportunistic infections may occur (5.1).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA205776 · Medexus
- First approved
- July 10, 2014 (12 years ago)
- Latest approved change
- March 11, 2020
- Approved label
- PDF, Mar 12, 2020
- Generic makers
- 16 approved generic applications on the market
- Last patent listed
- June 1, 2029
Rasuvo questions
How much does rasuvo cost without insurance?
Pharmacies pay about $577.45 for 0.8 mL of rasuvo 50 mg/mL, 0.2 mL auto-injector ($721.81 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $674.57. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Rasuvo?
Yes: methotrexate. Pharmacies pay from $3.50 for it. Compare methotrexate prices.
Is rasuvo in shortage?
Yes. 15 products are listed as in shortage or being discontinued (unavailable). See which ones.
Has rasuvo been recalled?
14 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the rasuvo label last change?
The official label was last updated on December 18, 2025 (version 10). See what changed.
Talk about rasuvo
No comments yet. Questions, tips, what worked for you - start the conversation.